Drug Discovery World

APRIL 6, 2023

The workshop will be led by hfp consulting, a firm which specialises in career development and leadership training for scientists. This session will take place during the meeting on Saturday, 15 April, 2023 at 11:45 PM – 3:45 PM EST. Location: Orange County Convention Center, Rooms W 340AB.

Small Molecule 130

Small Molecule Targeted Protein Degradation Clinical Trials Engineering 130

Drug Target Review

JULY 4, 2023

Over the last two decades, an increasing number of Antibody Drug Conjugate (ADC) therapeutics have been approved for oncology indications. These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Target Review

SEPTEMBER 25, 2024

However, this will not be straightforward, given that non-oncogene resistance is driven by complex transcriptional networks, and the key drivers that determine how these mechanisms could be targets for drug development remain elusive. This orally available small molecule binds to the bromodomain of CBP/p300 in a highly specific manner.

Small Molecule 105

Small Molecule Regulations Therapies Treatment 105

Drug Discovery World

MARCH 2, 2023

DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will take place on March 8, 2023 3PM GMT. This free event is ideal for research scientists and managers working in small molecule drug discovery. Register here for free.

Small Molecule 130

Small Molecule Drugs Research Drug Development 130

Drug Discovery World

FEBRUARY 23, 2023

DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will take place on March 8, 2023 3PM GMT. This free event is ideal for research scientists and managers working in small molecule drug discovery. Register here for free.

Small Molecule 130

Small Molecule Drugs Research Drug Development 130

Drug Discovery World

FEBRUARY 16, 2023

DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will take place on March 8, 2023 3PM GMT. This free event is ideal for research scientists and managers working in small molecule drug discovery. Register here for free.

Small Molecule 130

Small Molecule Drugs Research Drug Development 130

Drug Discovery World

FEBRUARY 9, 2023

DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will take place on March 8, 2023 3PM GMT. This free event is ideal for research scientists and managers working in small molecule drug discovery. Register here for free.

Small Molecule 130

Small Molecule Drugs Research Drug Development 130

Drug Discovery World

FEBRUARY 2, 2023

DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will take place on March 8, 2023 3PM GMT. This free event is ideal for research scientists and managers working in small molecule drug discovery. Register here for free.

Small Molecule 130

Small Molecule Drugs Research Drug Development 130

Drug Discovery World

FEBRUARY 22, 2023

In 2019 I forecast the arrival of AI in the drug discovery process, in 2023 we are seeing that this approach is now commonplace in molecule design, preclinical selection and the running of clinical trials.

Small Molecule 130

Small Molecule Drug Development Drugs Packaging 130

Drug Discovery World

NOVEMBER 8, 2023

While traditional approaches to clinical trials have helped us manage some of these conditions to a certain extent, they alone may not provide us the velocity we need to accelerate the research and conquer these diseases, raising the possibility that technologies such as artificial intelligence (AI) may hold the answer.

Clinical Trials 182

Clinical Trials Trials Disease Medical Schools 182

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. This appears to be supported by the number of Chinese collaborations, approvals and expansions in 2023 alone.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

FEBRUARY 27, 2023

For founders planning to launch their start-ups, specifically drug developers, there needs to be sound, foundational science with promising data that will enable you to push further down the drug discovery pipeline. DS: How is Atomic AI “unlocking the next generation of RNA drug discovery”? RT : Definitely yes.

RNA 130

RNA Science Small Molecule Engineering 130

Drug Discovery World

APRIL 12, 2023

This paid-for advertorial by IRBM appeared in DDW Volume 24 – Issue 2, Spring 2023 The landscape for treating rare cancers is changing with advances in molecular genetics, novel drug modalities and patient-derived models. Such insights are helping drug hunters to design novel drug development strategies.

Drugs 130

Drugs Small Molecule Treatment Drug Development 130

Drug Target Review

NOVEMBER 6, 2023

Advances in research and development and the utilisation of combination treatment strategies are revolutionising the haematology care landscape, but more must be done to address patients’ individual needs. To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required.

Small Molecule 111

Small Molecule Therapies Treatment Immune Response 111

LifeSciVC

JANUARY 16, 2024

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Just in time for new years’ reflections and resolutions, this year’s JPM felt like a refreshing burst of enthusiasm for a sector that has seen its challenges in 2022 and 2023 but also some green shoots. Small molecule GLP1s?

Small Molecule 139

Small Molecule Trials Therapies Disease 139

Vial

DECEMBER 11, 2023

In the decades since its identification in 1989, advances in clinical research for new Hepatitis C therapies and the introduction of direct-acting antiviral agents (DAAs) have led to viral eradication in more than 98% of patients, resulting in HCV crossing from manageable to being the first curable , chronic viral infection.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

PPD

JUNE 27, 2024

In recent years, AA has followed in the footsteps of other dermatology indications — including psoriasis and atopic dermatitis — with growing research and clinical studies focusing on small molecules with broad cellular effects (JAK and PDE4 inhibitors) and cytokine-specific molecules antagonists (IL-23, Th2 and IL17) to treat the condition.

Treatment 52

Treatment Clinical Trials Small Molecule Clinical Research 52

PPD

OCTOBER 18, 2023

Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030. 1 With this growth comes increased demands for laboratory services at all steps across the development process.

Laboratories 52

Laboratories Assay Development Small Molecule Packaging 52

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. Here, DDW’s Megan Thomas highlights the research taking place and where this is happening. One of the research themes at the university is Discovery of Medicines, which hosts the Cancer Research UK Newcastle Drug Discovery Unit.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

APRIL 25, 2023

The Autumn Statement in 2022 saw the UK Chancellor Jeremy Hunt cut the SME R&D tax relief rate, meaning SMEs would only receive half the cash co-investment from government they are expecting from April 2023 onwards, creating deficits in their future budgets. Each zone will receive £80m of support over five years.

Science 130

Science Small Molecule Disease Government 130

Sygnature Discovery

OCTOBER 10, 2023

On 10th October 2023, Sygnature Discovery, a world-leading integrated drug discovery provider and non-clinical solutions provider, has announced a scientific collaboration with human induced pluripotent stem cell (iPSC) experts, Axol Bioscience.

Small Molecule 52

Small Molecule Drugs Disease Clinical Trials 52

The Pharma Data

MARCH 28, 2022

Dupixent peak sales ambition raised to more than €13 billion Chronic obstructive pulmonary disease 2023 pivotal readouts provide potential for additional Dupixent sales ambition upgrade 13 potential new medicines currently in the clinic to treat chronic inflammatory diseases, with 17 readouts expected by the end of 2024. John Reed , M.

Small Molecule 52

Small Molecule Clinical Development Disease Science 52

Drug Discovery World

JULY 11, 2023

While the potential for better insights has grown, acquiring powerful tools that can harness that data, and turn it into useful, actionable information, has increasingly become one of the most important aspects of life science research. Advances in quantum computing are also showing early promise for increasingly complex data analyses.

Science 100

Science Drugs FDA Engineering 100

Drug Discovery World

JANUARY 26, 2023

DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year. As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities.

Clinical Trials 246

Clinical Trials Drugs Trials Therapies 246

Drug Discovery World

JANUARY 20, 2023

This paid-for advertorial by CN Bio appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Despite advancements, the drug development process remains inefficient. OOC systems represent the next generation platform for predicting drug effects in humans. References DOI: 10.1016/j.apsb.2022.02.002

Drug Development 130

Drug Development Drugs Small Molecule Immune Response 130

Drug Discovery World

APRIL 12, 2023

This paid-for advertorial by CN Bio appeared in DDW Volume 24 – Issue 2, Spring 2023 Despite advancements, the drug development process remains inefficient. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.

Drug Development 130

Drug Development Drugs Small Molecule Immune Response 130

Drug Target Review

JULY 12, 2023

It also addresses challenges seen with traditional chemical or biological approaches in drug discovery, which often try to identify targets in cell lines that do not reliably exemplify a disease in relevant patient populations. We are pleased that to date our lead product candidate has aligned DCI profiles as expected.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Agency IQ

APRIL 19, 2024

Meet C3TI, FDA’s new clinical trial innovation hub On April 14, FDA announced that its Center for Drug Evaluation and Research (CDER) is launching a new clinical trial innovation hub, the CDER Center for Clinical Trial Innovation (C3TI). In particular, regulations in both the U.S.

Clinical Trials 40

Clinical Trials Trials Science FDA 40

Drug Discovery World

AUGUST 2, 2023

PPT1 inhibitors for the treatment of patients with cancer Contemplating the potential of PPT1 inhibition in cancer led to the development of small molecules with high PPT1 affinity and limited toxicity for clinical drug development. He previously developed a Phase I and translational unit at Gustave Roussy.

Small Molecule 130

Small Molecule Immune Response Clinical Trials International 130

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues. Asia, and Europe.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

Conversations in Drug Development Trends

MAY 30, 2024

These advancements have fostered increased focus from politicians, policymakers, and the investment communities backing academic and industry-sponsored research projects. Researchers established efficacy of edaravone in a 24 week, randomized, placebo-controlled double-blind study in 137 Japanese patients.

Treatment 81

Treatment Small Molecule Clinical Trials Therapies 81

Conversations in Drug Development Trends

APRIL 4, 2024

Since reaching full implementation on January 21, 2023, numerous regulatory bodies have adopted the ICH M10 standards. Stability Tests: For small molecule, only -20°C stability testing is required, while large molecule need both -20°C and -70°C tests if samples are intended for storage at these temperatures.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals International 80

Drug Discovery World

OCTOBER 17, 2023

BN : Expression analysis and imaging-based analyses have indeed been performed by completely separate groups of researchers so far, with little to no interaction between them. This limits its efficacy in later stages of drug development or in the discovery and characterisation of biomarkers.

Disease 130

Disease Small Molecule Drugs RNA 130

Alta Sciences

JUNE 2, 2023

Expert Support for Your IND/CTA Requirements rmaloney Fri, 06/02/2023 - 17:33 HTML Partnering with Altasciences for your IND/CTA needs will ensure that your application to regulatory agencies moves forward as smoothly and efficiently as possible. Image alta-blog.jpg Tags Preclinical Research Contact our experts today.

Small Molecule 40

Small Molecule Drug Development Research Drugs 40

Agency IQ

DECEMBER 11, 2023

The FDA and oncology: 2023 year in review As we round the corner into the last few weeks of 2023, AgencyIQ has taken a look back at a very busy year for the FDA’s oncology staff, and for sponsors. OCE leadership and staff also kept AgencyIQ staff very busy in 2023 as they attended and presented at countless meetings.

FDA 40

FDA Science Clinical Trials Trials 40

Agency IQ

JUNE 9, 2023

BY RACHEL COE, MSC JUN 6, 2023 5:00 PM CDT What are nonclinical studies and when are they conducted in drug development? However, this guideline is primarily intended to provide recommendations on evaluating the immune system’s response to small molecule drugs.

FDA 40

FDA Science Small Molecule Immune Response 40

New Drug Approvals

SEPTEMBER 13, 2024

4] [6] Aticaprant was originally developed by Eli Lilly , was under development by Cerecor for a time, and is now under development by Janssen Pharmaceuticals. [2] 12] Positron emission tomography imaging revealed that brain KORs were almost completely saturated by the drug 2.5 Progress in Brain Research.

Treatment 62

Treatment Pharmacokinetics Clinical Trials Pharmaceuticals 62